Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
JOIN THE CLUB
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
GO AD-FREE

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you downgrade to Basic or cancel with-in 10 days of first subscribing, we will refund your payment upon request. Immediately after downgrading or cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BioSyent Inc. (V:RX)

Business Focus: Pharmaceuticals

Log in or join to add this stock to your watch list.
May 21, 2019 04:00 am ET
BioSyent Schedules Q1 2019 Earnings Release for May 29, 2019
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2019 on Wednesday, May 29, 2019.  A presentation on the Company’s first quarter 2019 results by René Goehrum,...
May 13, 2019 12:01 pm ET
BioSyent Announces Health Canada Approval of New Women’s Health Product
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Tibella® (tibolone), indicated for the short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one...
May 02, 2019 06:51 am ET
FeraMAX® Named #1 by Canadian Physicians and Pharmacists for Fourth Consecutive Year
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the fourth consecutive year, FeraMAX®  has been named the #1 recommended iron supplement brand in a national survey of Canadian physicians and pharmacists. The 2019...
Mar 22, 2019 12:01 pm ET
BioSyent Announces Notice of Deficiency for Cardiovascular Products
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that it has been informed by Health Canada that the Company will receive a Notice of Deficiency (“NOD”) with respect to its New Drug Submissions of two cardiovascular products for...
Mar 20, 2019 04:00 am ET
BioSyent Releases Results for Fourth Quarter and Full Year 2018
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and twelve months ended December 31, 2018. Key highlights include: Fourth quarter (Q4) 2018 Net Revenues of $5,910,965 increased by 0.2%...
Mar 15, 2019 08:35 am ET
BioSyent Schedules Q4 2018 Earnings Release for March 20, 2019
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and twelve months ended December 31, 2018 on Wednesday, March 20, 2019.  A presentation on the Company’s fourth quarter 2018 results by...
Dec 04, 2018 03:00 am ET
BioSyent Announces Normal Course Issuer Bid
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent...
Nov 21, 2018 03:00 am ET
BioSyent Releases Results for Third Quarter and First Nine Months of 2018
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and nine months ended September 30, 2018. Key highlights include: Third quarter (Q3) 2018 Net Revenues of $5,259,493 decreased...
Nov 08, 2018 04:22 am ET
BioSyent Schedules Q3 2018 Earnings Release for November 21, 2018
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2018 on Wednesday, November 21, 2018.  A presentation on the Company’s third quarter 2018 results...
Sep 13, 2018 05:00 am ET
BioSyent Named to the Growth 500 Ranking of Canada's Fastest-Growing Companies for Sixth Consecutive Year
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been named to the annual Growth 500 ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s.  The Growth 500 ranks Canadian businesses on...
Sep 10, 2018 01:28 pm ET
BioSyent Announces Changes to Executive Management
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced changes to its Executive Management team: Effective on September 10, 2018, Mr. Alfred D’Souza has retired as Vice President, Finance and Chief Financial Officer of the...
Aug 24, 2018 08:00 am ET
BioSyent to Present at Upcoming Investor Conference
BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture: RX) is pleased to announce that it will be presenting at the Midwest IDEAS Investor Conference at The Gwen in Chicago, Illinois. Mr.  René  Goehrum, BioSyent’s President  and  CEO, will...
Aug 22, 2018 04:00 am ET
BioSyent Releases Q2 and H1 2018 Results
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30, 2018. Key highlights include: Record second quarter (Q2) 2018 Net Revenues of $5,909,423 increased by 5%...
Aug 10, 2018 04:00 am ET
BioSyent Schedules Q2 2018 Earnings Release for August 22, 2018
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2018 on Wednesday, August 22, 2018.  A presentation on the Company’s second quarter 2018 results by René...
May 30, 2018 04:00 am ET
BioSyent Releases Results for Q1 2018
BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three months ended March 31, 2018. Key highlights include: First quarter (Q1) 2018 Net Revenues of $4,447,147 increased by 16% versus Q1 2017Q1...
May 17, 2018 04:00 am ET
BioSyent Schedules Q1 2018 Earnings Release for May 30, 2018
BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture:RX) will be reporting its financial results for the first quarter ended March 31, 2018 on Wednesday, May 30, 2018.  A presentation on the Company’s first quarter 2018 results by René Goehrum,...
May 01, 2018 04:00 am ET
FeraMAX® Named #1 by Canadian Physicians and Pharmacists for Third Consecutive Year
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) is pleased to announce that for the third consecutive year, FeraMAX® has been named the #1 recommended iron supplement brand in a national survey of Canadian physicians...
Apr 25, 2018 07:45 am ET
BioSyent to Present at Upcoming Investor Conferences
TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) is pleased to announce that it will be presenting at the following upcoming investor conferences:
Mar 21, 2018 04:00 am ET
BioSyent Releases Results for Fourth Quarter and Full Year 2017
TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2017. Key highlights include:
Mar 08, 2018 03:00 am ET
BioSyent Schedules Fourth Quarter 2017 Earnings Release for March 21, 2018
TORONTO, March 08, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”) (TSX Venture:RX) will be reporting its financial results for the fourth quarter and fiscal year ended December 31, 2017 on Wednesday, March 21, 2018.  A presentation...
Jan 08, 2018 01:09 pm ET
BioSyent Announces Changes to Its Board of Directors
TORONTO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) today announced the retirement of two long-serving Directors, Mr. Douglas Larson and Mr. Milton Wakefield, from its Board of Directors.  BioSyent also announced the appointment of...
Nov 15, 2017 03:00 am ET
BioSyent Releases Results for Third Quarter and First Nine Months of 2017
TORONTO, Nov. 15, 2017 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three and nine months ended September 30, 2017. Key highlights include:
Nov 08, 2017 10:29 am ET
BioSyent Schedules Q3 2017 Earnings Release for November 15, 2017
TORONTO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) will be reporting its financial results for the three and nine months ended September 30, 2017 on Wednesday, November 15, 2017 at 8:00am (ET).  A presentation...
Aug 16, 2017 06:45 am ET
BioSyent Releases Q2 and H1 2017 Results - CORRECTION
TORONTO, Aug. 16, 2017 (GLOBE NEWSWIRE) -- BioSyent Inc.’s (“BioSyent”) (TSX Venture:RX) press release issued at 8:00am ET on August 16, 2017 contained erroneous information regarding the grant of incentive stock options. This press release has been revised with corrected information regarding the grant of incentive stock options:...
May 25, 2017 04:00 am ET
BioSyent Releases Q1 2017 Results
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three months ended March 31, 2017. Key highlights include:
May 25, 2017 03:58 am ET
BioSyent Releases Q1 2017 Results
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three months ended March 31, 2017. Key highlights include: First quarter (Q1) 2017 Net Revenues of $3,821,262...
May 16, 2017 04:00 am ET
BioSyent Schedules Q1 2017 Earnings Release for May 25, 2017
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) will be reporting its financial results for the three months ended March 31, 2017 on Thursday, May 25, 2017 at 8:00am (ET). A presentation on the Company's first quarter 2017 results by Mr. Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.
May 16, 2017 03:58 am ET
BioSyent Schedules Q1 2017 Earnings Release for May 25, 2017
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) will be reporting its financial results for the three months ended March 31, 2017 on Thursday, May 25, 2017 at 8:00am (ET). A presentation on the Company's first quarter 2017 results by Mr. René...
May 01, 2017 04:00 am ET
FeraMAX(R) Named #1 by Canadian Physicians and Pharmacists for Second Consecutive Year
Editors note: There is one image accompanying this press release.
May 01, 2017 03:58 am ET
FeraMAX(R) Named #1 by Canadian Physicians and Pharmacists for Second Consecutive Year
Editors note: There is one image accompanying this press release. BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that FeraMAX® has been named the #1 recommended iron supplement brand in a national survey of...
Apr 24, 2017 04:00 am ET
BioSyent to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference on May 1st, 2017 at 3:00pm ET at the Sheraton Centre Toronto Hotel, Toronto, Ontario. Mr. Rene Goehrum, President and CEO, will present to investors an overview of BioSyent's business and corporate activities. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference on May 1st and 2nd. These one-on-one meetings can be requested by attendees through the online conference
Apr 24, 2017 03:58 am ET
BioSyent to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference on May 1st, 2017 at 3:00pm ET at the Sheraton Centre Toronto Hotel, Toronto,...
Apr 20, 2017 12:00 pm ET
BioSyent Extends In-License Agreement for Cathejell(R)
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. ("BioSyent Pharma"), has extended its License, Distribution and Supply Agreement with its European partner, Pharmazeutische Fabrik Montavit Ges.m.b.H., which gives BioSyent Pharma exclusive Canadian rights to the Cathejell(R) Jelly 2% product until March 31, 2024.
Apr 20, 2017 11:58 am ET
BioSyent Extends In-License Agreement for Cathejell(R)
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. ("BioSyent Pharma"), has extended its License, Distribution and Supply Agreement with its European partner, Pharmazeutische...
Mar 15, 2017 04:00 am ET
BioSyent Releases Results for Fourth Quarter and Full Year 2016
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three and twelve months ended December 31, 2016. Key highlights include:
Mar 15, 2017 03:58 am ET
BioSyent Releases Results for Fourth Quarter and Full Year 2016
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2016. Key highlights include: 2016 Net Revenues of $17,922,270...
Mar 06, 2017 03:00 am ET
BioSyent Schedules Fourth Quarter 2016 Earnings Release for March 15, 2017
BioSyent Inc. ("BioSyent", "the Company") (TSX VENTURE: RX) will be reporting its financial results for the fourth quarter and fiscal year ended December 31, 2016 on Wednesday, March 15, 2017. A presentation on the Company's fourth quarter 2016 results by Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.
Mar 06, 2017 02:58 am ET
BioSyent Schedules Fourth Quarter 2016 Earnings Release for March 15, 2017
BioSyent Inc. ("BioSyent", "the Company") (TSX VENTURE:RX) will be reporting its financial results for the fourth quarter and fiscal year ended December 31, 2016 on Wednesday, March 15, 2017. A presentation on the Company's fourth quarter 2016...
Dec 12, 2016 02:00 pm ET
BioSyent Announces Sale of Shares
BioSyent Inc. ("BioSyent", "the company") (TSX VENTURE: RX) President & CEO Rene Goehrum has advised the company that he has sold 300,000 shares in a single block to an existing institutional shareholder of BioSyent in a non-open market transaction. Mr. Goehrum continues to be the largest shareholder of BioSyent, holding a total of 2,245,261 BioSyent shares either directly or indirectly.
Dec 12, 2016 01:58 pm ET
BioSyent Announces Sale of Shares
BioSyent Inc. ("BioSyent", "the company") (TSX VENTURE:RX) President & CEO René Goehrum has advised the company that he has sold 300,000 shares in a single block to an existing institutional shareholder of BioSyent in a non-open market...
Nov 23, 2016 03:00 am ET
BioSyent Releases Results for Third Quarter and First Nine Months of 2016
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three and nine months ending September 30, 2016. Key highlights include:
Nov 23, 2016 02:58 am ET
BioSyent Releases Results for Third Quarter and First Nine Months of 2016
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three and nine months ending September 30, 2016. Key highlights include: First nine months (YTD) 2016 Net Revenues...
Nov 14, 2016 03:00 am ET
BioSyent Pharma Launches New Urgent Care Product
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has launched a new urgent care product, phenylephrine hydrochloride injection in the Aguettant System(R) pre-filled syringe ("Phenylephrine PFS"), for use in hospitals and acute care settings. The Company has already received two purchasing organization listings which give it access to more than 800 hospitals in Canada. In response to customer orders, shipments of the product have commenced.
Nov 14, 2016 02:58 am ET
BioSyent Pharma Launches New Urgent Care Product
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has launched a new urgent care product, phenylephrine hydrochloride injection in the Aguettant System® pre-filled syringe...
Nov 08, 2016 03:00 am ET
BioSyent Signs Exclusive Agreement for New Women's Health Product
BioSyent Inc. ("BioSyent")(TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma International Inc. has signed an exclusive License and Supply Agreement with a European partner for a new product in the women's health therapeutic area for the Canadian market. The product has been approved in Europe and in certain other markets around the world and will be launched in Canada after approval by Health Canada. BioSyent intends to submit the dossier seeking marketing approval of the product to Health Canada in 2017.
Nov 08, 2016 02:58 am ET
BioSyent Signs Exclusive Agreement for New Women's Health Product
BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) is pleased to announce that its subsidiary BioSyent Pharma International Inc. has signed an exclusive License and Supply Agreement with a European partner for a new product in the women's health therapeutic...
Nov 07, 2016 03:00 am ET
BioSyent Schedules Q3 2016 Earnings Release for November 23, 2016
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) will be reporting its financial results for the three and nine months ending September 30, 2016 on Wednesday, November 23(rd). A presentation on the Company's third quarter 2016 results by Mr. Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.
Nov 07, 2016 02:58 am ET
BioSyent Schedules Q3 2016 Earnings Release for November 23, 2016
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) will be reporting its financial results for the three and nine months ending September 30, 2016 on Wednesday, November 23rd. A presentation on the Company's third quarter 2016 results by Mr. René...
Sep 15, 2016 05:15 am ET
BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 815%
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that Canadian Business and PROFIT today named BioSyent to the 28th annual PROFIT 500, the definitive ranking of Canada's Fastest-Growing Companies. Published in the October issue of Canadian Business and at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their five-year revenue growth.
Sep 15, 2016 05:13 am ET
BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 815%
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that Canadian Business and PROFIT today named BioSyent to the 28th annual PROFIT 500, the definitive ranking of Canada's Fastest-Growing Companies. Published in the October issue of...
Aug 12, 2016 04:00 am ET
BioSyent Releases Q2 and H1 2016 Results
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three and six months ending June 30, 2016. Key highlights include:
Aug 12, 2016 03:58 am ET
BioSyent Releases Q2 and H1 2016 Results
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three and six months ending June 30, 2016. Key highlights include: Second quarter (Q2) 2016 Net Revenues of...
Aug 08, 2016 04:00 am ET
BioSyent Schedules Q2 2016 Earnings Release for August 12, 2016
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) will be reporting its financial results for the three and six months ending June 30, 2016 on Friday, August 12th at 8:00am (EST). A presentation on the Company's second quarter 2016 results by Mr. Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.
Aug 08, 2016 03:58 am ET
BioSyent Schedules Q2 2016 Earnings Release for August 12, 2016
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) will be reporting its financial results for the three and six months ending June 30, 2016 on Friday, August 12th at 8:00am (EST). A presentation on the Company's second quarter 2016 results by Mr....
May 27, 2016 04:00 am ET
BioSyent Releases Q1 2016 Results
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three months ending March 31, 2016. Key highlights include:
May 27, 2016 03:58 am ET
BioSyent Releases Q1 2016 Results
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three months ending March 31, 2016. Key highlights include: First quarter (Q1) 2016 Net Revenues of $3,772,463...
May 26, 2016 04:00 am ET
FeraMAX(R) Named #1 by Canadian Doctors and Pharmacists
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that its FeraMAX(R) brand was recently named as the #1 recommended over-the-counter ("OTC") iron supplement brand in a national survey of Canadian physicians and pharmacists.
May 26, 2016 03:58 am ET
FeraMAX(R) Named #1 by Canadian Doctors and Pharmacists
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its FeraMAX® brand was recently named as the #1 recommended over-the-counter ("OTC") iron supplement brand in a national survey of Canadian physicians and...
May 25, 2016 10:00 am ET
IIROC Trading Resumption - RX
VANCOUVER, May 25, 2016 /CNW/ - Trading resumes in:
May 25, 2016 09:44 am ET
IIROC Trading Halt - RX
VANCOUVER, May 25, 2016 /CNW/ - The following issues have been halted by IIROC:
May 25, 2016 08:53 am ET
BioSyent Signs Exclusive Distribution Agreement for Two New Cardiovascular Products
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its subsidiary BioSyent Pharma International Inc. has signed an exclusive Distribution Agreement with a European partner for two new products in the cardiovascular therapeutic...
May 25, 2016 08:53 am ET
BioSyent Signs Exclusive Distribution Agreement for Two New Cardiovascular Products
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma International Inc. has signed an exclusive Distribution Agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market. The products have been approved in Europe and in certain other markets around the world and will be launched in Canada if approval is granted by Health Canada. BioSyent intends to submit the dossier seeking marketing approval of the products to Health Canada in 2016.
May 25, 2016 06:01 am ET
BioSyent Schedules Q1 2016 Earnings Release for May 27, 2016
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) will be reporting its financial results for the three months ending March 31, 2016 on Friday, May 27, 2016 at 8:00am (EST). A presentation on the Company's first quarter 2016 results by Mr. Rene Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release.
May 25, 2016 06:01 am ET
BioSyent Schedules Q1 2016 Earnings Release for May 27, 2016
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) will be reporting its financial results for the three months ending March 31, 2016 on Friday, May 27, 2016 at 8:00am (EST). A presentation on the Company's first quarter 2016 results by Mr. René...
May 05, 2016 04:00 am ET
BioSyent Pharma Receives Health Canada Approval for New Urgent Care Product Using the Aguettant System(R)
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX)(OTC PINK: BIOYF) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received approval from Health Canada for a new urgent care product, phenylephrine hydrochloride injection in the Aguettant System(R) pre-filled syringe (PFS), for use in hospitals and acute care settings.
May 05, 2016 03:58 am ET
BioSyent Pharma Receives Health Canada Approval for New Urgent Care Product Using the Aguettant System(R)
BioSyent Inc. ("BioSyent") (TSX VENTURE:RX)(OTC PINK:BIOYF) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received approval from Health Canada for a new urgent care product, phenylephrine hydrochloride injection in the...
Apr 06, 2016 10:07 am ET
BioSyent to Present at Upcoming Investor Conferences
BioSyent Inc. ("BioSyent")(TSX VENTURE:RX)(OTC PINK:BIOYF) is pleased to announce that it will be presenting at the following upcoming investor conferences: April 7, 2016 - Laurentian Bank Securities Annual Institutional Investor Conference...
Apr 06, 2016 10:07 am ET
BioSyent to Present at Upcoming Investor Conferences
BioSyent Inc. ("BioSyent")(TSX VENTURE: RX)(OTC PINK: BIOYF) is pleased to announce that it will be presenting at the following upcoming investor conferences:
Mar 04, 2016 03:00 am ET
BioSyent Releases Q4 and Full Year 2015 Results
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX)(OTC PINK: BIOYF) released today a summary of its financial results for the three and twelve months ending December 31, 2015. Key highlights include: